Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Molecular Targeting Agents in Cancer Therapy: Science and Society

  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The inception of targeted agents has revolutionized the cancer therapy paradigm, both for physicians and patients. A large number of molecular targeted agents for cancer therapy are currently available for clinical use today. Many more are in making, but there are issues that remain to be resolved for the scientific as well as social community before the recommendation of their widespread use in may clinical scenarios can be done, one such issue being cost and cost effectiveness, others being resistance and lack of sustained efficacy. With the current knowledge about available targeted agents, the growing knowledge of intricate molecular pathways and unfolding of wider spectrum of molecular targets that can really matter in the disease control, calls for only the just use of the agents available now, drug companies need to make a serious attempt to reduce the cost of the agents. Research should focus on agents that show sustained responses in preclinical data. More needs to be done in laboratories and by the pharmaceutical industries, before we can truly claim to have entered a new era of targeted therapy in cancer care.

Keywords

References

  1. Barbara M, Bolten MS, Matthew Drapeau MBA, et al (2010). Strategic Overview of the Targeted Cancer Therapies Marketplace. http://decisionresources.com/.
  2. Baselga J, Perez EA, Pienkowski T, Bell R (2006). Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist, 11, 4-12. https://doi.org/10.1634/theoncologist.11-90001-4
  3. Blumenthal D (2004). Doctors and drug companies. N Engl J Med, 351, 1885-90. https://doi.org/10.1056/NEJMhpr042734
  4. Cohen EE (2008). mTOR: the mammalian target of replication. J Clin Oncol, 26, 348-9. https://doi.org/10.1200/JCO.2007.14.3164
  5. Coiffier B, Thieblemont C, Van Den Neste E, et al (2010). Longterm outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 116, 2040-5. https://doi.org/10.1182/blood-2010-03-276246
  6. DiMasi JA, Hansen RW, Grabowski HG (2003). The price of innovation: new estimates of drug development costs. J Health Econ, 22, 151-85. https://doi.org/10.1016/S0167-6296(02)00126-1
  7. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391-400. https://doi.org/10.1038/nrd1381
  8. Folkman J (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182-6. https://doi.org/10.1056/NEJM197111182852108
  9. Grillo-Lopez AJ, White CA, Varns C, et al (1999). Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol, 26, 66-73.
  10. Hallberg B, Palmer RH (2010). Crizotinib-latest champion in the cancer wars? N Engl J Med, 363, 1760-2. https://doi.org/10.1056/NEJMe1010404
  11. Hornberger JC, Best JH (2005). Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer, 103, 1644-51. https://doi.org/10.1002/cncr.20956
  12. Http://ramoslink.info/pubs/GlivecPAP.pdf : (2010). NICE denies availability of Sorafenib liver cancer drug on NHS, http://www.news-medical.net.
  13. Llovet JM, Ricci S, Mazzaferro V, et al (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90. https://doi.org/10.1056/NEJMoa0708857
  14. Maggon K (2007). Monoclonal antibody "gold rush". Curr Med Chem, 14, 1978-87. https://doi.org/10.2174/092986707781368504
  15. Mok TS, Wu YL, et al (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 361, 947-57. https://doi.org/10.1056/NEJMoa0810699
  16. Murawski N, Pfreundschuh M (2010). New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol, 11, 1074-85. https://doi.org/10.1016/S1470-2045(10)70210-2
  17. Ocana A, Amir E, Seruga B, Pandiella A, et al (2010). Do we have to change the way targeted drugs are developed? J Clin Oncol, 28, 420-1. https://doi.org/10.1200/JCO.2010.28.9918
  18. Ronald D, Levy DGM, Miller R (2008). Targeted Therapy for B-Cell Lymphoma: The Story of Rituximab. Special ASH 50th anniversary brochure.
  19. Rosenwald A, Wright G, Chan WC, et al (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346, 1937-47. https://doi.org/10.1056/NEJMoa012914
  20. Spurling GK, Mansfield PR, Montgomery BD, et al (2010). Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med, 7, 1000352.
  21. Staff Writer (2010). FDA considers revoking approval of Avastin for advanced breast cancer. Washington Post. Washington.
  22. Valentino L, Pierre J (2006). JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol, 71, 713-21. https://doi.org/10.1016/j.bcp.2005.12.017
  23. van Oosterom AT, Judson I, Verweij J, et al (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 358, 1421-3. https://doi.org/10.1016/S0140-6736(01)06535-7

Cited by

  1. Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay vol.36, pp.3, 2018, https://doi.org/10.1200/JCO.2017.74.2577